key: cord-0972032-lk0e3m06
authors: Jevtic, Stefan D.; Morris, Andrew M.; Warkentin, Theodore E.; Pai, Menaka
title: Heparin-induced thrombocytopenia
date: 2021-05-17
journal: CMAJ
DOI: 10.1503/cmaj.210637
sha: 35cde56b13ead7c03a56c038b287e0190b9af74d
doc_id: 972032
cord_uid: lk0e3m06

nan

A 4Ts score estimates pretest probability of HIT compared with other causes of thrombocytopenia, assessing platelet count, timing, sequelae and causes. 2 Screening is usually performed by immunologic assays (e.g., enzyme-linked immunosorbent assay [ELISA]). If positive, a confirmatory platelet activation test (e.g., serotonin-release assay) is required as many patients with a positive ELISA result do not have HIT.

Warfarin should be avoided and vitamin K administered if warfarin has already been given, because of the risk of warfarin-associated microthrombosis. 3 Factor Xa inhibitors (fondaparinux, apixaban, rivaroxaban) and thrombin inhibitors (argatroban, bivalirudin, dabigatran) should be considered if the patient needs anticoagulation. Intravenous immunoglobulin may be beneficial in atypical, severe HIT. 4 Patients should be referred to a hematologist if possible.

Clinical features of VITT include thrombocytopenia and unusual thrombi, including cerebral venous sinus thrombosis and splanchnic vein thrombosis. 5 A 4Ts score, substituting "vaccine" for "heparin," can be used. Treatment for VITT is similar to that for HIT but emphasizes high-dose intravenous immunoglobulin. Diagnostic testing for VITT antibodies is available in Canada (McMaster Platelet Immunology Laboratory, in Hamilton, Ont.). PRACTICE | FIVE THINGS TO KNOW ABOUT ... 

An improved definition of immune heparin-induced thrombocytopenia in postoperative orthopedic patients

Predictive value of the 4Ts scoring system for heparin-induced thrombocytopenia: a systematic review and meta-analysis

The pathogenesis of venous limb gangrene associated with heparininduced thrombocytopenia

High-dose intravenous immunoglobulin for the treatment and prevention of heparin-induced thrombocytopenia: a review

Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination

Competing interests: Theodore Warkentin reports receiving grants from Instrumentation Laboratory, royalties from Informa (Taylor & Francis), consulting fees from Aspen Global and Ergomed, lecture honoraria from Alexion Canada and Instrumentation Laboratory, and payment for providing expert witness testimony relating to heparin-induced thrombocytopenia (HIT) and non-HIT thrombocytopenic and coagulopathic disorders. Dr. Warkentin has participated on advisory boards for CSL Behring and Octapharma and been a member of a committee on disseminated intravascular coagulation for the International Society on Thrombosis and Haemostasis. Menaka Pai reports receiving royalties from UpToDate and support for attending a conference from Scripps. No other competing interests were declared. This article has been peer reviewed.